Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

Marianne Davies,1–3 Emily A Duffield3 1Yale School of Nursing, 2Department of Medical Oncology, Yale Comprehensive Cancer Center, 3Department of Nursing, Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT, USA Abstract: Immune checkpoint inhibitors (ICPIs), in the fo...

Full description

Bibliographic Details
Main Authors: Davies M, Duffield EA
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:ImmunoTargets and Therapy
Subjects:
immune-mediated adverse event
checkpoint inhibitor
immunotherapy
CTLA-4
PD-1
PD-L1
Online Access:https://www.dovepress.com/safety-of-checkpoint-inhibitors-for-cancer-treatment-strategies-for-pa-peer-reviewed-article-ITT

Internet

https://www.dovepress.com/safety-of-checkpoint-inhibitors-for-cancer-treatment-strategies-for-pa-peer-reviewed-article-ITT

Similar Items